Cast


Peregrine Pharmaceuticals Inc. (PPHM)

(NasdaqCM: PPHM)

SUMMARY

 
 

Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM

Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential wrongdoing at Peregrine Inc. (“Peregrine” or the “Company”) (NASDAQ: PPHM).  The investigation focuses on whether certain executive officers and directors of Peregrine breached their fiduciary duties by failing to disclose that:  (1) there were major discrepancies between various patient sample test results and patient treatment code assignments; (2) the clinical data from the Company’s randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer was misleading; and (3) as a result of the foregoing, the Company’s positive statements about Peregrine’s business, operations, and prospects, including those statements relating to the clinical data from the Company’s randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer lacked sufficient support.

On September 24, 2012 Peregrine disclosed that during the course of preparing for an end-of-phase II meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer, the Company discovered major conflicts between patient sample test results and patient treatment code assignments. Moreover, Peregrine informed investors that they should no longer depend on clinical data that the Company had previously reported from its Phase II bavituximab trial in patients with second-line non-small cell lung cancer.  Shareholders interested in seeking to recover damages on behalf of Peregrine and to implement corporate governance measures designed to prevent future misconduct should contact the firm.

If you hold PPHM shares and you would like to discuss your legal rights, you can contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to mhynes@faruqilaw.com.

 
 

Request Information

 
  Please tell us about yourself by completing the form below and we will provide you with additional
information on how to join the Action.
Company:Peregrine Pharmaceuticals Inc. (PPHM)
 
 
 
   
 
 

Contact Counsel

Michael J. Hynes
Faruqi & Faruqi, LLP
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Tel: (215) 277-5770
Email:  mhynes@faruqilaw.com

Send Information

If you have information regarding this case that you would
like to make available, please click here to contact us
about our investigation